Domain specific BET inhibitors for cancer therapy
| Reference number | |
| Coordinator | SARomics Biostructures AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | June 2018 - May 2019 |
| Status | Completed |
Important results from the project
The purpose of the project is to develop a BET bromodomain inhibitor (BETi) with differentiated safety and selectivity profile for the treatment of Myc-driven cancers. The series of substances developed during this project has promising properties and represents a potential future treatment for patients with solid malignances and resistance cancer forms with poor prognosis.
Expected long term effects
Our solution will provide several benefits for the individual patient, healthcare and society. With the developed series of BETi candidates, we get an opportunity to treat resistant cancers, and with a future defined patient population, we will have a better degree of efficiency and cost efficient treatment. The project already has and will in the long term contribute to employment opportunities and R&D training and training opportunities in drug development in Sweden.
Approach and implementation
The project work has been carried out in four different work packages by an experienced interdisciplinary team with expertise in clinical development, cancer biology, drug chemistry and drug design from three different organizations. Cooperation has worked excellent and the positive result can be seen as a direct result of this.